GlobeNewswire: Revive Therapeutics Ltd. Contains the last 10 of 177 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T15:21:14ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/27/2853251/0/en/Revive-Therapeutics-Submits-Type-C-Meeting-Request-Package-to-FDA-for-Clinical-Study-of-Bucillamine-to-Treat-Long-COVID.html?f=22&fvtc=4&fvtv=44703Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID2024-03-27T13:08:48Z<![CDATA[TORONTO, March 27, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that it has submitted a Type C meeting request package to the U.S. Food & Drug Administration (“FDA”) for the evaluation of a proposed clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long-term COVID. Following the submission of the Type C meeting request package, the Company expects to hear from the FDA on a firm date for the meeting.]]>https://www.globenewswire.com/news-release/2024/03/19/2848420/0/en/Revive-Therapeutics-To-Submit-Type-C-Meeting-Request-with-FDA-for-Bucillamine-to-Treat-Long-COVID.html?f=22&fvtc=4&fvtv=44703Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID2024-03-19T11:00:00Z<![CDATA[TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that the FDA advised the Company to submit a Type C meeting request to discuss evaluating a proposed Phase 2 clinical study of Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID. The Company expects to submit the Type C meeting request by next week.]]>https://www.globenewswire.com/news-release/2024/03/12/2844382/0/en/Revive-Therapeutics-Provides-Corporate-Update.html?f=22&fvtc=4&fvtv=44703Revive Therapeutics Provides Corporate Update2024-03-12T11:00:00Z<![CDATA[TORONTO, March 12, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today a corporate update on the research, clinical and regulatory initiatives with Bucillamine and its long COVID diagnostic product.]]>https://www.globenewswire.com/news-release/2024/02/26/2835487/0/en/Revive-Therapeutics-Ltd-Announces-Closing-of-the-Second-and-Final-Tranche-of-Its-Private-Placement-for-Gross-Proceeds-of-1-187-110.html?f=22&fvtc=4&fvtv=44703Revive Therapeutics Ltd. Announces Closing of the Second and Final Tranche of Its Private Placement for Gross Proceeds of $1,187,1102024-02-26T21:05:00Z<![CDATA[NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN]]>https://www.globenewswire.com/news-release/2024/02/01/2821891/0/en/Revive-Therapeutics-Explores-the-Use-of-Bucillamine-for-Long-COVID.html?f=22&fvtc=4&fvtv=44703Revive Therapeutics Explores the Use of Bucillamine for Long COVID2024-02-01T12:30:00Z<![CDATA[TORONTO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today its initiative in Bucillamine, an oral thiol-based drug with anti-inflammatory and antiviral properties, as a potential treatment for long COVID. The Company aims to advance the clinical development of Bucillamine by leveraging the published research and existing data from its previous Phase 3 clinical trial (the “Study”) and is preparing a clinical package that includes a proposed Phase 2/3 clinical protocol for long COVID to present to the FDA and international health regulatory bodies.]]>https://www.globenewswire.com/news-release/2024/01/31/2821606/0/en/Revive-Therapeutics-Ltd-Announces-Closing-of-the-First-Tranche-of-Its-Private-Placement-for-Gross-Proceeds-of-913-500.html?f=22&fvtc=4&fvtv=44703Revive Therapeutics Ltd. Announces Closing of the First Tranche of Its Private Placement for Gross Proceeds of $913,5002024-01-31T22:06:22Z<![CDATA[NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN]]>https://www.globenewswire.com/news-release/2024/01/24/2816162/0/en/Revive-Therapeutics-Ltd-Announces-Offering-of-Up-to-3-Million.html?f=22&fvtc=4&fvtv=44703Revive Therapeutics Ltd. Announces Offering of Up to $3 Million2024-01-24T22:55:40Z<![CDATA[NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN]]>https://www.globenewswire.com/news-release/2024/01/16/2809707/0/en/Revive-Therapeutics-Provides-Update-Evaluating-Bucillamine-for-Nerve-Agent-Exposure-with-Defence-Research-and-Development-Canada.html?f=22&fvtc=4&fvtv=44703Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada2024-01-16T12:00:00Z<![CDATA[TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today announced an update on the Company’s project evaluating Bucillamine as a potential treatment for nerve agent exposure with Defence R&D Canada – Suffield Research Centre (“DRDC”), an agency of the Canadian Department of National Defence. The Company and the DRDC have finalized the research protocol and expect the project to be completed by the end of Q2-2024.]]>https://www.globenewswire.com/news-release/2024/01/10/2806975/0/en/Revive-Therapeutics-Successfully-Completes-Development-of-a-Novel-Lyophilized-Formulation-of-Bucillamine.html?f=22&fvtc=4&fvtv=44703Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine2024-01-10T12:00:00Z<![CDATA[TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has completed the formulation development work of the Company’s next-generation lyophilized formulation of Bucillamine (“New Bucillamine”) conducted at the University of Waterloo. The New Bucillamine has the potential to unlock the therapeutic utility of Bucillamine for treating public health medical emergencies, including pandemic influenza, emerging infectious diseases, and medical countermeasure incidents and attacks.]]>https://www.globenewswire.com/news-release/2023/12/20/2799564/0/en/Revive-Therapeutics-Announces-Results-of-Annual-General-and-Special-Meeting-of-Shareholders.html?f=22&fvtc=4&fvtv=44703Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders2023-12-20T17:54:19Z<![CDATA[TORONTO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the results of its annual general and special meeting of shareholders held Tuesday, December 19, 2023 (the “Meeting”) in Toronto, Ontario. All matters presented to the shareholders of the Company (the “Shareholders”) for approval as set out in the Company's Notice of Meeting and Information Circular, dated November 10, 2023 respectively, were approved by an overwhelming majority of votes cast at the Meeting. Of the 357,646,841 shares issued and outstanding on the record date for the Meeting, 143,297,862 shares, being 40% of the shares, were voted.]]>